Opaleye Management as of June 30, 2024
Portfolio Holdings for Opaleye Management
Opaleye Management holds 51 positions in its portfolio as reported in the June 2024 quarterly 13F filing
| Company (Ticker) | Portfolio Weight | Valued At | Change in Shares | Share Count | Share Price |
|---|---|---|---|---|---|
| Harrow Health (HROW) | 19.0 | $83M | 4.0M | 20.89 | |
| Tg Therapeutics (TGTX) | 9.3 | $41M | 2.3M | 17.79 | |
| Ocular Therapeutix (OCUL) | 8.3 | $36M | 5.3M | 6.84 | |
| Rhythm Pharmaceuticals (RYTM) | 4.8 | $21M | 515k | 41.06 | |
| Keros Therapeutics (KROS) | 3.8 | $17M | 368k | 45.70 | |
| Arvinas Ord (ARVN) | 3.4 | $15M | 555k | 26.62 | |
| Immunome (IMNM) | 3.0 | $13M | 1.1M | 12.10 | |
| Cytokinetics Com New (CYTK) | 2.5 | $11M | 199k | 54.18 | |
| Codexis (CDXS) | 2.4 | $11M | 3.5M | 3.10 | |
| Edgewise Therapeutics (EWTX) | 2.4 | $10M | 580k | 18.01 | |
| Catalyst Pharmaceutical Partners (CPRX) | 2.3 | $9.9M | 640k | 15.49 | |
| Cargo Therapeutics (CRGX) | 2.1 | $9.1M | 556k | 16.42 | |
| Jasper Therapeutics Com New (JSPR) | 2.0 | $8.9M | 392k | 22.70 | |
| Nurix Therapeutics (NRIX) | 2.0 | $8.7M | 419k | 20.87 | |
| Trevi Therapeutics (TRVI) | 1.8 | $7.9M | 2.6M | 2.98 | |
| Eton Pharmaceuticals (ETON) | 1.8 | $7.9M | 2.4M | 3.29 | |
| Applied Therapeutics (APLT) | 1.8 | $7.8M | 1.7M | 4.67 | |
| 4d Molecular Therapeutics In (FDMT) | 1.7 | $7.3M | 346k | 20.99 | |
| Iovance Biotherapeutics (IOVA) | 1.6 | $7.2M | 897k | 8.02 | |
| Acelyrin | 1.6 | $7.0M | 1.6M | 4.41 | |
| Urogen Pharma (URGN) | 1.6 | $6.9M | 412k | 16.78 | |
| Vaxcyte (PCVX) | 1.5 | $6.4M | 85k | 75.51 | |
| Biodesix (BDSX) | 1.4 | $6.2M | 4.0M | 1.53 | |
| Newamsterdam Pharma Company Ordinary Shares (NAMS) | 1.4 | $6.1M | 315k | 19.21 | |
| Xoma Corp Del Com New (XOMA) | 1.4 | $5.9M | 250k | 23.69 | |
| Protara Therapeutics Com Stk (TARA) | 1.2 | $5.3M | 2.3M | 2.30 | |
| Intellia Therapeutics (NTLA) | 1.1 | $4.9M | 218k | 22.38 | |
| Nuvalent Inc-a (NUVL) | 1.0 | $4.5M | 59k | 75.86 | |
| Syros Pharmaceuticals Com New (SYRS) | 1.0 | $4.5M | 865k | 5.16 | |
| Gossamer Bio Note 5.000% 6/0 (Principal) | 0.9 | $4.0M | 8.0M | 0.49 | |
| Liquidia Corporation Com New (LQDA) | 0.9 | $3.9M | 325k | 12.00 | |
| Karyopharm Therapeutics Note 3.000%10/1 (Principal) | 0.9 | $3.7M | 6.0M | 0.62 | |
| Protagonist Therapeutics (PTGX) | 0.8 | $3.6M | 105k | 34.65 | |
| Gossamer Bio (GOSS) | 0.8 | $3.5M | 3.9M | 0.90 | |
| Lexicon Pharmaceuticals Com New (LXRX) | 0.7 | $3.2M | 1.9M | 1.68 | |
| Savara (SVRA) | 0.7 | $2.9M | 715k | 4.03 | |
| Allakos | 0.6 | $2.8M | 2.8M | 1.00 | |
| Ventyx Biosciences (VTYX) | 0.6 | $2.7M | 1.2M | 2.31 | |
| Verastem Com New (VSTM) | 0.6 | $2.7M | 915k | 2.98 | |
| Regulus Therapeutics | 0.6 | $2.6M | 1.5M | 1.78 | |
| Lyell Immunopharma | 0.6 | $2.4M | 1.7M | 1.45 | |
| Relmada Therapeutics (RLMD) | 0.4 | $1.8M | 600k | 3.00 | |
| Fulcrum Therapeutics (FULC) | 0.4 | $1.8M | 285k | 6.20 | |
| Karyopharm Therapeutics | 0.3 | $1.2M | 1.4M | 0.87 | |
| Ibio Com New (IBIO) | 0.2 | $791k | 375k | 2.11 | |
| Pmv Pharmaceuticals (PMVP) | 0.2 | $770k | 475k | 1.62 | |
| Aerovate Therapeutics (AVTE) | 0.2 | $730k | 440k | 1.66 | |
| Design Therapeutics (DSGN) | 0.2 | $687k | 205k | 3.35 | |
| Abcellera Biologics (ABCL) | 0.1 | $592k | 200k | 2.96 | |
| Aligos Therapeutics | 0.1 | $441k | 1.3M | 0.35 | |
| Reneo Pharmaceuticals (RPHM) | 0.1 | $249k | 165k | 1.51 |
